CONCORDBIO: Stable Q3 with strong margins and 10% nine-month revenue growth; 25% CAGR outlook maintained

About this update from Concord Biotech Ltd.

Q3 FY25 saw stable results with 1% revenue growth and strong margins, while nine-month revenue rose 10% year-over-year, led by a 42% increase in formulations. Management maintains a 25% CAGR growth outlook, with new product launches, capacity ramp-up, and sustainability initiatives supporting future performance.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Concord Biotech Ltd.